A 3-year randomized therapeutic trial of nitisinone in alkaptonuria

Molecular Genetics and Metabolism

Volumn 103, Issue 4, 2011, Pages 307-314

  Introne, Wendy J ^a   Perry, Monique B ^b   Troendle, James ^c   Tsilou, Ekaterini ^d   Kayser, Michael A ^a,f   Suwannarat, Pim ^a,g   O'Brien, Kevin E ^a,b   Bryant, Joy ^a   Sachdev, Vandana ^c   Reynolds, James C ^e   Moylan, Elizabeth ^b   Bernardini, Isa ^a   Gahl, William A ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Warren Clinic   (United States)

^g KAISER PERMANENTE   (United States)

Author keywords

Alkaptonuria; Homogentisic acid; Nitisinone; Ochronosis

Indexed keywords

4 HYDROXYPHENYLPYRUVATE DIOXYGENASE; CREATINE KINASE; DILTIAZEM; HOMOGENTISIC ACID; NITISINONE; PHENYLALANINE; PROTEIN; TYROSINE;

ADULT; AGED; ALKAPTONURIA; AMINO ACID BLOOD LEVEL; ANEMIA; AORTA ATHEROSCLEROSIS; AORTA STENOSIS; ARTICLE; BIOCHEMISTRY; BLOOD LEVEL; BONE DENSITY; CARDIOVASCULAR RISK; CHOLECYSTECTOMY; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON BILE DUCT STONE; CONTROLLED STUDY; CORNEA INJURY; CORNEA OPACITY; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GENERAL CONDITION DETERIORATION; HEART ATRIUM FIBRILLATION; HIP ARTHROPLASTY; HUMAN; HYPERTRANSAMINASEMIA; IRON DEFICIENCY ANEMIA; MALE; MEDIASTINUM ADENOPATHY; MEDIASTINUM DISEASE; MUSCULOSKELETAL FUNCTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN DEGRADATION; PROTEIN RESTRICTION; RANDOMIZED CONTROLLED TRIAL; RANGE OF MOTION; REPEAT PROCEDURE; SARCOIDOSIS; SIDE EFFECT; TREATMENT DURATION; TYROSINEMIA; URINE LEVEL;

4-HYDROXYPHENYLPYRUVATE DIOXYGENASE; ADULT; ALKAPTONURIA; CYCLOHEXANONES; HOMOGENTISIC ACID; HUMANS; MIDDLE AGED; NITROBENZOATES; PROSPECTIVE STUDIES; TYROSINE;

EID: 79960845905     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.04.016     Document Type: Article

References (29)

1. Garrod A.E. About alkaptonuria. Lancet 1901, 158:1484-1486.
2. Garrod A.E. The Croonian lectures on inborn errors of metabolism. Lecture II. Alkaptonuria. Lancet 1908, 172:73-79.
3. Piro A., Tagarelli A., Tagarelli G., Lagonia P., Quattrone A. Archibald Edward Garrod: the physician father of biochemistry. Metabolism: Clinical and Experimental 2009, 58:427-437.
4. La Du B.N., Zannoni V.G., Laster L., Seegmiller J.E. The nature of the defect in tyrosine metabolism in alcaptonuria. The Journal of Biological Chemistry 1958, 230:251-260.
5. O'Brien W.M., La Du B.N., Bunim J. Biochemical, pathologic and clinical aspects of alcaptonuria, ochronosis, and ochronotic arthropathy. The American Journal of Medicine 1963, 34:813-838.
6. Kayser M.A., Introne W., Gahl W.A. Alkaptonuria. Online Metabolic and Molecular Bases of Inherited Disease 2007, McGraw-Hill, New York. D. Valle, A. Beaudet, B. Vogelstein, K. Kinzler, S. Antonarakis, A. Ballabio, C.R. Scriver, W.S. Sly, B. Childs (Eds.).
7. Milch R.A. Studies of alcaptonuria: mechanisms of swelling of homogentisic acid-collagen preparations. Arthritis and Rheumatism 1961, 4:253-267.
8. Milch R.A., Murray R.A. Studies of alcaptonuria: adsorption of homogentisic acid solutions on collagen chromatographic columns. Arthritis and Rheumatism 1961, 4:268-274.
9. La Du B.N., O'Brien W.M., Zannoni V.G. Studies on ochronosis. I. The distribution of homogentisic acid in guinea pigs. Arthritis and Rheumatism 1962, 5:81-87.
10. Zannoni V.G., Malawista S.E., La Du B.N. Studies on ochronosis. II. Studies on benzoquinoneacetic acid, a probale intermediate in the connective tissue pigmentation of alcaptonuria. Arthritis and Rheumatism 1962, 5:547-556.
11. Zannoni V.G., Lomtevas N., Goldfinger S. Oxidation of homogentisic acid to ochronotic pigment in connective tissue. Biochimica et Biophysica Acta 1969, 177:94-105.
12. Introne W.J., Kayser M.A., Gahl W.A. Alkaptonuria, GeneReviews at Gene Tests: Medical Genetics Information Resource July 2009, [database online], University of Washington, Seattle, Updated.
13. Phornphutkul C., Introne W.J., Perry M.B., Bernardini I., Murphey M.D., Fitzpatrick D.L., Anderson P.D., Huizing M., Anikster Y., Gerber L.H., Gahl W.A. Natural history of alkaptonuria. The New England Journal of Medicine 2002, 347:2111-2121.
14. Anikster Y., Nyhan W.L., Gahl W.A. NTBC and alkaptonuria. American Journal of Human Genetics 1998, 63:920-921.
15. Suwannarat P., O'Brien K., Perry M.B., Sebring N., Bernardini I., Kaiser-Kupfer M.I., Rubin B.I., Tsilou E., Gerber L.H., Gahl W.A. Use of nitisinone in patients with alkaptonuria. Metabolism: Clinical and Experimental 2005, 54:719-728.
16. Ahmad S., Teckman J.H., Lueder G.T. Corneal opacities associated with NTBC treatment. American Journal of Ophthalmology 2002, 134:266-268.
17. Holme E., Lindstedt S. Tyrosinaemia type I and NTBC. Journal of Inherited Metabolic Disease 1998, 21:507-517.
18. Gissen P., Preece M.A., Willshaw H.A., McKiernan P.J. Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. Journal of Inherited Metabolic Disease 2003, 26:13-16.
19. Lustberg T.J., Schulman J.D., Seegmiller J.E. The preparation and identification of various adducts of oxidized homogentisic acid and the development of a new sensitive colorimetric assay for homogentisic acid. Clinica Chimica Acta 1971, 35:325-333.
20. Moll J., Wright V. Normal range of spinal mobility: an objective clinical study. Annals of the Rheumatic Diseases 1971, 30:381-386.
21. Enright P., Sherrill D. Reference equations for the six-minute walk in healthy adults. American Journal of Respiratory and Critical Care Medicine 1998, 158:1384-1387.
22. Steffen T., Hacker T., Mollinger L. Age and gender-related test performance in community-dwelling elderly people: six-minute walk test, berg balance scale, timed up and go test, and gait speed. Physical Therapy 2002, 82:128-137.
23. Podsiadlo D., Richardson S. The timed up and go: a test of basic functional mobility for frail elderly persons. Journal of the American Geriatrics Society 1991, 39:142-148.
24. Schober P. Ledenwirbel saoule und kreuzachmerchen. Munchener medizinische Wochenschrift 1937, 84:366.
25. Macrae I., Wright V. Measurement of back movement. Annals of the Rheumatic Diseases 1969, 28:584.
26. Motion T.C.o.J. Joint Motion: Method of Measuring and Recording 1965, American Academy of Orthopedic Surgeons, Chicago.
27. Sniderman King L., Trahms C., Scott C.R. Tyrosinemia Type 1, GeneReviews at Gene Tests: Medical Genetics Information Resource October 2008, [database online], University of Washington, Seattle, Updated.
28. Introne W.J., Phornphutkul C., Bernardini I., McLaughlin K., Fitzpatrick D., Gahl W.A. Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation. Molecular Genetics and Metabolism 2002, 77:136-142.
29. Scott C.R. The genetic tyrosinemias. American Journal of Medical Genetics. Part C, Seminars in Medical Genetics 2006, 142C:121-126.